Tuberculosis Vaccine Candidate to Prevent Disease Enters Clinical Testing

August 22nd, 2012|Press Releases|

Seattle, WA | August 22, 2012 Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI’s novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess [...]

IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant

August 16th, 2012|Press Releases|

Seattle, WA | August 16, 2012 The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical [...]

IDRI Receives $3.7 Million Grant for TB Drug Discovery

July 25th, 2012|Press Releases|

Seattle, WA | July 25, 2012 IDRI's drug discovery efforts continue to grow with a recently awarded five-year grant for $3.7 million from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The [...]

IDRI Expands Board, Adding Additional International Expertise

July 2nd, 2012|Press Releases|

Seattle, WA | July 2, 2012 The Infectious Disease Research Institute (IDRI) continues to expand its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Massimo Radaelli, Ph.D., who has 25 years [...]

Seven Pharmaceutical Companies Join Academic Researchers to Speed TB Drug Discovery

June 25th, 2012|Press Releases|

June 25, 2012 Seven pharmaceutical companies and four research institutions, working with the Bill & Melinda Gates Foundation, have launched a groundbreaking partnership that aims to speed the discovery of essential new treatments for tuberculosis (TB). The partnership, known [...]

IDRI Signs Lease with Alexandria Real Estate Equities, Inc. for New Seattle Headquarters

May 30th, 2012|Press Releases|

Seattle, WA | May 30, 2012 The Infectious Disease Research Institute (IDRI) has officially signed a new lease in Seattle’s South Lake Union neighborhood with long-time real estate partner Alexandria Real Estate Equities, Inc.  IDRI intends to relocate in [...]

AERAS and IDRI Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine

May 9th, 2012|Press Releases|

Rockville, MD | Seattle, WA | May 9, 2012 Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI’s novel tuberculosis vaccine candidate. This collaboration reflects the [...]

IDRI Quest for Leprosy Vaccine Closer to Reality with Help of Million Dollar Grant

March 8th, 2012|Press Releases|

Seattle, WA | March 8, 2012 Leprosy, otherwise referred to as Hansen's Disease, is one of the most ancient diseases known to humans. Although the World Health Organization declared leprosy to be under control in many previously endemic countries, [...]

First Vaccine Against Fatal Visceral Leishmaniasis Enters Clinical Trial

February 22nd, 2012|Press Releases|

Seattle, WA | February 22, 2012 The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat [...]

IDRI Supports the First Phase 1 Human Hookworm Vaccine Clinical Trial

January 31st, 2012|Press Releases|

Seattle, WA | January 31, 2012 The Infectious Disease Research Institute (IDRI) announced its technical support of the Sabin Vaccine Institute's (Sabin) first ever Phase 1 clinical trial of a human hookworm vaccine candidate, which began last week in [...]

Load More